Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Triple agonist peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
GLP-1, GIP and glucagon receptor agonism.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Reported weight management
Triple agonist distinct from retatrutide despite shared GLP-1/GIP/glucagon targets.
Human evidence
Phase 2 randomized trial in 205 adults with overweight/obesity reported weight reduction at 24 weeks; no diabetes population in that trial.
Preclinical evidence
Not the same molecule as retatrutide.
Critical reading and limitations
A 205-adult phase II trial supports a weight-loss signal, not chemical/clinical equivalence among triple agonists.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.
2 / 4 / 6 mg · Target amounts in separate arms
- Frequency
- Weekly
- Duration
- 24 weeks
- Route
- Subcutaneous
- Context
- 205 adults without type 2 diabetes; starting/escalation exposures differ by arm.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID42843337 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Mostly gastrointestinal adverse events reported; uncommon and long-term harms remain incompletely characterized.
Short duration/limited size poorly estimate rare or long-term harms.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
NCT07177469 · UBT251 Injection Phase II Study (Overweight or Obesity)Registry status: CompletedLast update posted: September 24, 2026Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
UBT251 · 14 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07668388 · A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesRegistry status: RecruitingLast update posted: October 7, 2026Query verification: October 16, 2026
NCT07177469 · UBT251 Injection Phase II Study (Overweight or Obesity)Registry status: CompletedLast update posted: September 24, 2026Query verification: October 16, 2026
NCT07163624 · UBT251 Injection Phase II (Type 2 Diabetes Mellitus) StudyRegistry status: CompletedLast update posted: September 21, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID42843337
Zhou Z, Cheng Z, Jin P, Yang G, Wang H, Shi B, Dong Q, Shi X, Shi X, Shu H, Sun W, Huang C, Zhao S, Mao L, Wang W, Xiong P, Chen X, Tian J, Zhang H, Su T, Huang L, Simony SB, Holst-Hansen T, Yan H.
October 16, 2026